Kinetics of Maternally Derived Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Infants in Relation to the Timing of Antenatal Vaccination | Zendy

Amihai Rottenstreich | Zendy; Gila Zarbiv | Zendy; Esther OiknineDjian | Zendy; Olesya Vorontsov | Zendy; Roy Zigron | Zendy; Geffen Kleinstern | Zendy; Shay Porat | Zendy; Dana G. Wolf | Zendy

Open Access

Kinetics of Maternally Derived Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Infants in Relation to the Timing of Antenatal Vaccination

Author(s) -

Amihai Rottenstreich,

Gila Zarbiv,

Esther OiknineDjian,

Olesya Vorontsov,

Roy Zigron,

Geffen Kleinstern,

Shay Porat,

Dana G. Wolf

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac480

Subject(s) - medicine , vaccination , transplacental , gestational age , pregnancy , antibody , pediatrics , gestation , fetus , immunology , obstetrics , placenta , biology , genetics

SARS-CoV-2 infection during early infancy can result in severe disease. We evaluated the durability of maternally-derived anti-SARS-CoV-2 antibodies in infants and its relation to antenatal vaccination timing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research